Semnurpharma - Getting back to normal

Getting back to normal

About
Partners
Chronic Back Pain
Science
Investors
Join Our Team
Contact Us

Publications

12

Jul

Date July 12, 2022

The pharmacokinetics andpharmacodynamics of dexamethasonefollowing epidural SP-102 orintravenous dexamethasone sodiumphosphate injection in subjects withlumbosacral radicular pain

Author uferes@scilexholding.com

Overview
Partners
Our Culture
Product
Publications
Join Our Team
Presentation
Contact Us

Connect, follow and have a conversation with us

960 San Antonio Road, Palo Alto, CA, 94303
(650) 516-4310
info@semnurpharma.com

Privacy Policy | Terms of Use | © 2025 All rights reserved.

Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), and Denali Capital Acquisition Corp. Announce the Closing of Their Previously Announced Business Combination

Check Our Press Release

Semnur Pharmaceuticals

Reference:
@srinipillay 2016:https://www.health.harvard.edu/blog/psychology-low-back-pain-201604259537

… heavy objects, or some other non-specific back injury.

Reference:
@srinipillay 2016: https://www.health.harvard.edu/blog/psychology-low-back-pain-201604259537

The overall estimated number of epidural steroid injection (ESI) procedures in the U.S. is approximately 12.1 million across all Medicare and private coverage patients, with lumbar radiculopathy/sciatica procedures comprising approximately 88% of all ESIs administered, according to a proprietary study by Syneos Health. *

References:
* Syneos Health

Reference:
@srinipillay 2016: https://www.health.harvard.edu/blog/psychology-low-back-pain-201604259537